Sarvenaz Mobasser, MD
Family Medicine · Los Angeles, CANPI 1295061786
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 98 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Amgen at 31.6% of the total. Reporting peaked in 2021 at $615 and has fallen 58.4% since, to $256 in 2025.
Across 98 payments — averaging $21.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$678
- AbbVie$537
- Lilly USA, LLC$341
- Gilead$118
- Biohaven Pharmaceutical Holding Company Ltd.$93
- Viiv Healthcare Company$78
- plus $300 from 8 others
What the payments were for
- Food & beverage$2,145100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 31 | $678 |
| AbbVie(2 entities) | 27 | $537 |
| Lilly USA, LLC | 14 | $341 |
| Gilead | 4 | $118 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $93 |
| Viiv Healthcare Company | 3 | $78 |
| Pfizer | 3 | $71 |
| Lundbeck LLC | 2 | $56 |
| Novo Nordisk | 3 | $52 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Abbott | 1 | $28 |
| Philips North America LLC | 1 | $18 |
| Botanix SB Inc | 1 | $17 |
How this compares
$2,145 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 30 | $21,750 |
| JanuviaSitagliptin Phosphate | 14 | $20,722 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 39 | $1,525 |
| Metoprolol Succinate | 18 | $376 |
| Atorvastatin Calcium | 26 | $330 |
| Metformin Hcl | 16 | $217 |
| Carvedilol | 13 | $217 |
| Ketoconazole | 11 | $180 |
| Fluticasone Propionate | 11 | $176 |
| Lisinopril | 19 | $151 |
| Omeprazole | 13 | $146 |
| Spironolactone | 14 | $121 |
| Losartan Potassium | 16 | $106 |
| Simvastatin | 12 | $85 |
| Amlodipine Besylate | 17 | $83 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Los Angeles
- Pamela KushnerLos Angeles$1.2M
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Jacqueline KenneyLos Angeles$121K
- Sherly SoleimanEncino$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Sandra CalmanMontara$589K
- Anthony JonesOakland$377K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.